Efficacy and Safety of Non-Pegylated Liposomal Doxorubicin in Metastatic Breast Cancer Therapy

OnCOReview - Poland
doi 10.24292/01.or.131217
Full Text
Abstract

Available in full text

Categories
Oncology
Date
Authors
Publisher

Medical Education

Related search

Pharmacokinetics and Efficacy of PEGylated Liposomal Doxorubicin in an Intracranial Model of Breast Cancer

PLoS ONE
Multidisciplinary
2013English

Safety and Efficacy of Pegylated Liposomal Doxorubicin in HIV-associated Kaposi’s Sarcoma

Biologics: Targets and Therapy
OncologyImmunologyGastroenterologyPharmacologyRheumatologyAllergy
2009English

Emerging Pharmacotherapies in Ovarian Cancer: Focus on Pegylated Liposomal Doxorubicin

Clinical Medicine Reviews in Women's Health
2010English

Multicenter Experience of Nonpegylated Liposomal Doxorubicin Use in the Management of Metastatic Breast Cancer

Clinical Breast Cancer
Cancer ResearchOncology
2014English

Non‑pegylated Liposomal Doxorubicin for Patients With Recurrent Ovarian Cancer: A Multicentric Phase II Trial

Oncology Letters
Cancer ResearchOncology
2016English

A Systematic Review and Economic Evaluation of Pegylated Liposomal Doxorubicin Hydrochloride for Ovarian Cancer

Health Technology Assessment
MedicineHealth Policy
2002English

Pegylated Liposomal Doxorubicin Plus Cyclophosphamide Followed by Docetaxel as Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer (Registration Number: ChiCTR1900023052)

Scientific Reports
Multidisciplinary
2019English

A Retrospective Analysis of Pegylated Liposomal Doxorubicin in Ovarian Cancer: Do We Still Need It?

Journal of Ovarian Research
GynecologyOncologyObstetrics
2013English

Pegylated Liposomal Doxorubicin in the Treatment of Primary Cutaneous T-Cell Lymphomas

Haematologica
Hematology
2007English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy